Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 2/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9715912 | 0.71 | CYP3A4 (0.33) | CYP3A4TDP1ESR1ESR2 | |
| SCHEMBL28635021 | 0.69 | TDP1 (0.50) | CYP3A4TDP1ESR1ESR2 | |
| SCHEMBL19538364 | 0.67 | TDP1 (0.43) | CYP3A4TDP1ESR1ESR2 | |
| Hydrochloric Acid SCHEMBL28467021 | 0.66 | CYP3A4 (0.47) | CYP3A4TDP1ESR1ESR2 | |
| SCHEMBL32679515 | 0.61 | CYP3A4 (0.47) | CYP3A4TDP1ESR1ESR2 | |
| SCHEMBL6289830 | 0.59 | TSHR (0.36) | TDP1 | |
| SCHEMBL322574 | 0.59 | TDP1 (0.45) | CYP3A4TDP1ESR1ESR2 | |
| SCHEMBL1646006 | 0.59 | TDP1 (0.45) | CYP3A4TDP1ESR1ESR2 | |
| SCHEMBL11661389 | 0.59 | TP53 (0.36) | ESR1 | |
| SCHEMBL2576486 | 0.58 | TDP1 (0.43) | CYP3A4TDP1ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10688473-B2 | Ligand compound, organic chromium compound, catalyst system for oligomerization of olefins, and method for oligomerizing olefins using the same | LG CHEM, LTD. (KR) | 2020-06-23 | — | — | US | disclosed |
| US-20170312738-A1 | LIGAND COMPOUND, ORGANIC CHROMIUM COMPOUND, CATALYST SYSTEM FOR OLIGOMERIZATION OF OLEFINS, AND METHOD FOR OLIGOMERIZING OLEFINS USING THE SAME | LG CHEM, LTD. (KR) | 2017-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10688473-B2 | Ligand compound, organic chromium compound, catalyst system for oligomerization of olefins, and method for oligomerizing olefins using the same | OXER1, OSTC, ORC3 | CYP3A4 751/4885TDP1 1826/4885ESR1 781/4885 |
| US-20170312738-A1 | LIGAND COMPOUND, ORGANIC CHROMIUM COMPOUND, CATALYST SYSTEM FOR OLIGOMERIZATION OF OLEFINS, AND METHOD FOR OLIGOMERIZING OLEFINS USING THE SAME | OXER1, OSTC, ORC3 | CYP3A4 751/4885TDP1 1826/4885ESR1 781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.